StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $9.90 | $9.88 | -0.20% | 0.0M |
| 05-12 | $9.57 | $9.32 | -2.61% | 0.0M |
| 05-13 | $9.50 | $9.45 | -0.53% | 0.0M |
| 05-14 | $9.51 | $10.30 | +8.31% | 0.0M |
| 05-15 | $10.00 | $9.81 | -1.90% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for NVNO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for NVNO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2019 2019-12-31 | Q3 2019 2019-09-30 | Q2 2019 2019-06-30 | Q1 2019 2019-03-31 |
|---|---|---|---|---|
Revenue | $31.24K | $31.24K | $31.24K | $31.24K |
Operating Income | $-7.68M | $-5.38M | $-3.54M | $-1.58M |
Net Income | $-7.63M | $-5.33M | $-1.95M | $-1.57M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $3.43M | $5.75M | $7.25M | $5.49M |
Total Liabilities | $2.44M | $2.67M | $2.60M | $2.62M |
Cash & Equivalents | $1.31M | $2.94M | $4.47M | $2.75M |
Free Cash Flow OCF − CapEx | $-6.26M | $-4.62M | $-3.10M | $-1.50M |
Shares Outstanding | 717.27K | 17.92M | 17.92M | 14.16M |
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.